CJC-1295 DAC (5MG)

What Is CJC-1295 DAC and Why Buy It for Research?

Buy CJC-1295 DAC in Switzerland for research into growth hormone axis signaling, sustained GH release, and long-acting GHRH analog pharmacology. Specifically, CJC-1295 DAC (also known as DAC:GRF or CJC-1295 with Drug Affinity Complex) is a synthetic 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH) that incorporates the first 29 residues of endogenous GHRH with a critical DAC extension. Structurally, it features the sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ with a maleimidopropionic acid DAC moiety attached to the lysine side chain at position 30.

CJC-1295 DAC represents a significant advancement in peptide research design. The compound incorporates four strategic amino acid substitutions—D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—that confer resistance to dipeptidyl peptidase-IV (DPP-IV) and other plasma proteases. Furthermore, the defining feature is the Drug Affinity Complex (DAC) moiety, which covalently binds to the free thiol group of cysteine-34 on endogenous serum albumin after administration, extending the plasma half-life to approximately 6-8 days. This albumin conjugation effectively circumvents the primary limitation of peptide drugs—rapid in vivo degradation. Moreover, Core Peptides supplies CJC-1295 DAC as a lyophilized powder in a 5mg format exclusively for laboratory use. Therefore, researchers seeking to source this long-acting GHRH analog for their work will find it readily available when they buy CJC-1295 DAC in Switzerland.

CJC-1295 DAC Research Overview: Buy CJC-1295 DAC in Switzerland for Long-Acting GHRH Studies

Centrally, research into CJC-1295 DAC has focused on its function as a long-acting GHRH analog that provides sustained stimulation of the growth hormone axis. Endogenously, growth hormone-releasing hormone (GHRH) stimulates the pituitary gland to release growth hormone (GH), which in turn stimulates the liver to produce and secrete insulin-like growth factor-1 (IGF-1). However, therapeutic and research use of native GHRH is limited by its short duration of action, with a half-life of approximately 7 minutes due to rapid enzymatic degradation.

CJC-1295 DAC overcomes this limitation through two key innovations. First, the tetrasubstituted amino acid backbone provides resistance to DPP-IV and other plasma proteases. Second, the DAC moiety covalently binds to circulating albumin after subcutaneous injection. This albumin conjugation extends the plasma half-life to approximately 6 to 8 days. A landmark 2006 Phase 1 randomized, placebo-controlled trial by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism, reported that a single subcutaneous dose of CJC-1295 DAC (1–30 mcg/kg) produced dose-dependent mean GH elevations of 2- to 10-fold and sustained IGF-1 elevations of 1.5- to 3-fold above baseline lasting 9 to 11 days. The estimated half-life in this study was 5.8-8.1 days. Accordingly, researchers who buy CJC-1295 DAC in Switzerland from Core Peptides can support their investigations into long-acting GHRH signaling, sustained GH and IGF-1 elevation, and growth hormone axis pharmacology.

How Does CJC-1295 DAC Work in Research?

Mechanistically, CJC-1295 DAC operates through a dual-action approach that combines receptor activation with sustained pharmacokinetic properties.

GHRH Receptor Activation

CJC-1295 DAC functions as a GHRH analog that binds to and activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs. This binding triggers a downstream signaling cascade via Gs/cAMP/PKA signaling that results in GH synthesis and secretion. Importantly, studies have demonstrated that pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, preserving the physiologic secretory pattern even under sustained stimulation.

Drug Affinity Complex (DAC) Technology

The defining feature of CJC-1295 DAC is the Drug Affinity Complex moiety. This maleimidopropionic acid group, attached to the lysine side chain at position 30, is engineered to react selectively with the free thiol group of cysteine-34 on serum albumin. Following subcutaneous administration, this covalent binding to endogenous albumin extends the half-life to approximately 6 to 8 days, as established in the Teichman 2006 phase II trial.

Sustained GH and IGF-1 Elevation

This albumin conjugation provides prolonged exposure to elevated GH and IGF-1 levels. After a single injection of CJC-1295 DAC, researchers observed dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 days. This sustained action leads to increased circulating levels of GH and IGF-1 with infrequent dosing.

Why Is CJC-1295 DAC Studied in Switzerland?

Primarily, researchers study CJC-1295 DAC because it represents a well-characterized long-acting GHRH analog that enables investigation of sustained GH axis stimulation, somatotroph biology, and growth hormone pharmacology. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying GH secretion, IGF-1 production, and growth hormone axis regulation.

Research has demonstrated CJC-1295 DAC’s efficacy across multiple domains. In a study using GHRH knockout mice, long-term treatment with CJC-1295 DAC normalized growth parameters and body composition, and stimulated somatotroph cell proliferation and GH production in the anterior pituitary. Furthermore, the Teichman 2006 clinical trial established the pharmacokinetic and pharmacodynamic profile in healthy adults, demonstrating sustained, dose-dependent increases in GH and IGF-I levels with good tolerability. Preclinical and clinical studies have shown that CJC-1295 DAC can stimulate proliferation of somatotrophs and increase GH production. Ultimately, researchers who buy CJC-1295 DAC in Switzerland gain access to a comprehensive research tool for investigating long-acting GHRH signaling, somatotroph biology, and growth hormone axis pharmacology.

CJC-1295 DAC Research Areas in Laboratory Studies

Research Area	Focus	Evidence Level
GH Axis Signaling	GHRH receptor activation, Gs/cAMP/PKA signaling, pulsatile GH secretion	Mechanistic / Preclinical / Clinical
Sustained GH Elevation	Prolonged GH release, dose-dependent GH increases (2-10 fold), pharmacokinetics	Clinical (Phase 1)
IGF-1 Regulation	Sustained IGF-1 elevation (1.5-3 fold), IGF-1 duration (9-11 days)	Clinical (Phase 1)
Somatotroph Proliferation	Pituitary cell proliferation, GH production, somatotroph biology	Preclinical
Albumin Conjugation	DAC technology, covalent albumin binding, extended half-life (6-8 days)	Pharmacokinetic
Growth and Body Composition	Growth normalization, body composition, GHRH knockout models	Preclinical
Long-Acting Peptide Design	DPP-IV resistance, tetrasubstituted analogs, peptide stability	Mechanistic

CJC-1295 DAC Compared With Related Research Compounds

Compound	Research Focus	Mechanism / Target	Key Difference
CJC-1295 DAC	Sustained GH/IGF-1 elevation, long-acting GHRH signaling	GHRH-R activation + DAC albumin conjugation	30-amino acid peptide; half-life 6-8 days; sustained elevation
CJC-1295 (No DAC / Mod GRF 1-29)	Pulsatile GH release, GHRH signaling	GHRH-R activation only	29-amino acid peptide; half-life ~30 minutes; pulsatile release
Tesamorelin	GHRH analog for lipodystrophy	GHRH-R activation	FDA-approved for HIV-associated lipodystrophy; shorter half-life
Sermorelin	GHRH analog for GH deficiency	GHRH-R activation	Short half-life; requires frequent administration

Comparatively, CJC-1295 DAC differs from other GHRH analogs in its extended pharmacokinetic profile. On the one hand, CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes and mimics the natural, pulsatile release of GHRH. On the other hand, CJC-1295 DAC achieves a half-life of approximately 6 to 8 days through covalent albumin binding, providing sustained GH and IGF-1 elevation. In contrast, tesamorelin and sermorelin have shorter half-lives and require more frequent administration.

Research Applications for CJC-1295 DAC in Switzerland

Scientists have investigated CJC-1295 DAC across several research domains:

• GH Axis Signaling Research: Researchers use CJC-1295 DAC to study GHRH receptor activation, Gs/cAMP/PKA signaling, and pulsatile GH secretion dynamics.
• Sustained GH and IGF-1 Studies: The compound is employed to investigate prolonged GH elevation, dose-dependent GH increases, and sustained IGF-1 regulation.
• Somatotroph Biology: Studies have examined CJC-1295 DAC’s effects on pituitary somatotroph proliferation, GH production, and cell population dynamics.
• Pharmacokinetic Research: The compound serves as a model for studying albumin conjugation, DAC technology, and extended half-life peptide design.
• Growth and Body Composition: Preclinical research has examined CJC-1295 DAC’s effects on growth normalization and body composition in GHRH-deficient models.
• Long-Acting Peptide Design: CJC-1295 DAC is used to investigate DPP-IV resistance, tetrasubstituted analogs, and peptide stability enhancement.

Evidently, researchers who buy CJC-1295 DAC in Switzerland gain a valuable addition to any laboratory toolkit focused on growth hormone axis signaling, long-acting peptide pharmacology, and somatotroph biology.

CJC-1295 DAC Product Specifications

Specification	Details
Product Name	CJC-1295 DAC (CJC-1295 with Drug Affinity Complex)
Alternative Names	DAC:GRF, CJC-1295 with DAC, CJC-1295 DAC, CJC 1295 DAC
Amount	5mg
Form	Lyophilized powder
Purity	Not verified
Amino Acid Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ (29-amino acid GHRH backbone + DAC extension)
Peptide Length	30 amino acids (29-amino acid backbone + DAC moiety)
Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂ (free base)
Molecular Weight	3,367.9 g/mol (free base; varies by salt form)
CAS Number	446262-90-4
Half-Life	Approximately 6-8 days (with DAC); ~30 minutes (without DAC)
Research Category	Growth Hormone Peptides / Anti-Aging & Longevity
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and bacteriostatic water; reconstitute slowly

How to Evaluate CJC-1295 DAC Quality for Research

When sourcing CJC-1295 DAC peptide for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the compound’s molecular weight and sequence.
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results including HPLC purity and identity confirmation.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, amount (5mg), sequence, molecular formula, CAS number, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptides and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation, purity percentage as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptide they are using in their laboratory investigations.

Storage and Stability of CJC-1295 DAC

Core Peptides supplies CJC-1295 DAC as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents (e.g., bacteriostatic water or sterile water)
• Inject solvent slowly against the inner wall of the vial rather than directly onto the powder; do not shake
• Gently roll the vial in a circular motion to dissolve
• Once reconstituted, refrigerate at 2°C to 8°C and utilize promptly
• Protect from light and moisture

Frequently Asked Questions About Buying CJC-1295 DAC in Switzerland

What is CJC-1295 DAC?

Specifically, CJC-1295 DAC (DAC:GRF) is a synthetic 30-amino acid long-acting analog of growth hormone-releasing hormone (GHRH) with Drug Affinity Complex technology that covalently binds to serum albumin, extending its half-life to approximately 6-8 days.

What is CJC-1295 DAC researched for?

Primarily, researchers study CJC-1295 DAC for its role in sustained GH and IGF-1 elevation, somatotroph proliferation, and long-acting GHRH signaling. Studies have investigated its pharmacokinetic profile, GH axis stimulation, and growth effects in preclinical and clinical models.

How does CJC-1295 DAC work?

Mechanistically, CJC-1295 DAC binds to and activates the GHRH receptor on pituitary somatotrophs, triggering GH synthesis and secretion via Gs/cAMP/PKA signaling. The DAC moiety covalently binds to serum albumin, extending the half-life to approximately 6-8 days.

What is the amino acid sequence of CJC-1295 DAC?

The amino acid sequence is Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂.

What is the molecular weight of CJC-1295 DAC?

The molecular weight is approximately 3,367.9 g/mol (free base).

What is the molecular formula of CJC-1295 DAC?

The molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂.

What is the CAS number of CJC-1295 DAC?

The CAS number is 446262-90-4.

What is the half-life of CJC-1295 DAC?

CJC-1295 DAC has a half-life of approximately 6-8 days due to covalent albumin binding. In the Teichman 2006 clinical trial, the estimated half-life was 5.8-8.1 days.

How does CJC-1295 DAC differ from CJC-1295 without DAC?

CJC-1295 DAC has a half-life of approximately 6-8 days due to albumin-binding DAC technology, while CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes and mimics natural pulsatile GHRH release.

What research exists on CJC-1295 DAC?

Research on CJC-1295 DAC includes the landmark 2006 Teichman Phase 1 clinical trial demonstrating sustained GH (2-10 fold) and IGF-1 (1.5-3 fold) elevations, preclinical studies in GHRH knockout mice showing growth normalization and somatotroph proliferation, and pharmacokinetic studies establishing the 6-8 day half-life.

Is CJC-1295 DAC approved as a medicine?

No. Regulatory authorities have not approved CJC-1295 DAC as a medicine, pharmaceutical, or therapeutic agent. It is a research tool for laboratory use only.

Is CJC-1295 DAC intended for human use?

No. CJC-1295 DAC is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy CJC-1295 DAC in Switzerland?

You can buy CJC-1295 DAC in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate CJC-1295 DAC quality?

Researchers should look for identity confirmation via mass spectrometry, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in CJC-1295 DAC may also find the following related compounds relevant to their work:

• CJC-1295 (Mod GRF 1-29) — The shorter-acting version without DAC, researched for pulsatile GH release and GHRH signaling.
• Tesamorelin — A GHRH analog researched for lipodystrophy and metabolic regulation.
• Sermorelin — A GHRH analog researched for GH deficiency and aging research.
• Ipamorelin — A GHRP researched for selective GH release with minimal cortisol elevation.

Explore Growth Hormone Peptides

CJC-1295 DAC belongs to the Growth Hormone Peptides category of research compounds. Growth Hormone Peptides products are studied for their potential roles in GH axis signaling, metabolic regulation, and growth-related pathways. Generally, researchers who buy CJC-1295 DAC in Switzerland often pair it with related compounds in this category to explore complementary pathways in GH research and metabolic studies.

Explore Anti-Aging & Longevity

Researchers studying age-related GH decline, metabolic health, and longevity pathways may also find relevant compounds in the Anti-Aging & Longevity category. CJC-1295 DAC’s effects on sustained GH and IGF-1 elevation make it a valuable tool for investigating age-related GH axis decline and metabolic research.

Further Research

For researchers seeking to deepen their understanding of CJC-1295 DAC and its research applications, the following areas may warrant further investigation:

• The relationship between CJC-1295 DAC-mediated sustained GH elevation and specific downstream signaling pathways in different cell types
• Comparative studies between CJC-1295 DAC and shorter-acting GHRH analogs in various GH axis and metabolic models
• The potential for DAC technology to provide insights into long-acting peptide design and albumin conjugation strategies
• Mechanistic studies on somatotroph proliferation and GH production in response to sustained GHRH stimulation
• Exploration of CJC-1295 DAC’s effects on different tissue systems beyond the GH axis

Research Disclaimer

CJC-1295 DAC is a research peptide supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving peptides should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.